Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Other Operating Expenses (2016 - 2025)

Lipocine's Other Operating Expenses history spans 13 years, with the latest figure at $607777.0 for Q3 2025.

  • For Q3 2025, Other Operating Expenses changed N/A year-over-year to $607777.0; the TTM value through Sep 2025 reached $1.3 million, down 75.69%, while the annual FY2024 figure was $3.3 million, 6.43% down from the prior year.
  • Other Operating Expenses reached $607777.0 in Q3 2025 per LPCN's latest filing, up from -$952571.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $3.5 million in Q4 2023 to a low of -$1.8 million in Q3 2023.
  • Average Other Operating Expenses over 5 years is $676136.2, with a median of $874721.0 recorded in 2024.
  • The largest YoY upside for Other Operating Expenses was 3.66% in 2025 against a maximum downside of 208.9% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at -$1.0 in 2021, then surged by 88795400.0% to $887953.0 in 2022, then soared by 291.38% to $3.5 million in 2023, then tumbled by 80.64% to $672872.0 in 2024, then dropped by 9.67% to $607777.0 in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Other Operating Expenses are $607777.0 (Q3 2025), -$952571.0 (Q2 2025), and $952571.0 (Q1 2025).